Reduction in the frequency of hospitalizations, by delaying additional episodes of acute decompensated heart failure; and Weaning patients with severe heart failure who are currently dependent on ...
The study, the second of the Randomized Evaluations of Levosimendan (REVIVE-2), is the first randomized double-blind controlled trial evaluating clinical course, not merely surrogate end points, ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results